Autres langues Alterity Therapeutics Limited Nasdaq

Actions

ATHE

US02155X2053

Recherche biotechnologique et médicale

Temps Différé Nasdaq 19:45:40 03/09/2026			Varia. 5j.	Varia. 1 janv.
4,460 ^USD	-1,33%		-2,19%	+44,81%

31/08	Alterity Therapeutics conclut un accord de prise ferme pour l'exercice de jusqu'à 8,4 millions d'options cotées	MT
28/08	Alterity Therapeutics Limited publie ses résultats pour l'exercice clos le 30 juin 2026	CI

Autres langues

31/08	Alterity Therapeutics Enters Underwriting Agreement for Exercise of up to 8.4 Million Listed Options
28/08	Alterity Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2026
12/08	Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
12/08	Alterity Therapeutics Announces Granting Of New U.S. Composition Of Matter Patent For ATH434
12/08	Alterity Therapeutics Secures New Patent for Oral Drug Candidate for Neurodegenerative Diseases; Shares Up 7%
09/07	Alterity Therapeutics Receives AU$4 Million Tax Refund From Australian Government
07/07	Alterity Therapeutics Limited Receives FDA End-Of-Phase 2 Meeting Minutes Confirming Registrational Pathway For ATH434 In Multiple System Atrophy
07/07	Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy
07/07	Alterity Therapeutics Says US FDA Meeting Minutes Confirm Key Elements of Phase 3 MSA Treatment Candidate Program; Shares Fall 4%
09/06	Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For ATH434 In Multiple System Atrophy
03/06	Alterity Therapeutics Limited Announces Change of Registered Office Address
19/05	Alterity Therapeutics Announces Data Presentations Supporting Advancement Of ATH434 Into Phase 3 In Multiple System Atrophy
19/05	Alterity Therapeutics Says Data Presentations Support Phase Three Development for Multiple System Atrophy Treatment Candidate
19/05	Alterity Therapeutics : Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
11/05	Alterity Therapeutics Announces Utility of Quantitative Mri as Biomarker for Multiple System Atrophy
11/05	Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%
11/05	Alterity Therapeutics : Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
07/05	Alterity Therapeutics : to Deliver Presentations at Multiple Medical Conferences in May 2026
27/04	Alterity Therapeutics Receives Positive FDA Feedback on Ath434 Phase 3 Program in Multiple System Atrophy
27/04	Alterity Therapeutics Secures US FDA Support for ATH434 Phase Three Program
27/04	Alterity Therapeutics receives positive FDA feedback on ATH434 phase 3 program
22/04	Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
17/04	Alterity Therapeutics Limited Appoints Ann Cunningham as Independent Non-Executive Director, Effective April 17, 2026
30/03	Alterity Therapeutics Limited Receives Positive FDA Feedback on Ath434 Phase 3 Program
30/03	Alterity Therapeutics Receives Positive FDA Feedback After Type C Meeting on Planned Third-Phase Program